RxDoctor Payments Data

Juan Rico

Pediatric Hematology-Oncology · Tampa, FLNPI 1790912665

Payments from drug & device makers

What this record shows

Novartis accounts for 66.5% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $989 and has fallen 61.9% since, to $377 in 2023.

$1,489in general payments, 2019–2025

Across 9 payments — averaging $165.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$989
  • Heartflow, Inc.$191
  • Biomarin Pharmaceutical Inc.$140
  • Global Blood Therapeutics, Inc.$122
  • Abbott$47
$487,695in research payments, 2019–2025

Across 207 payments — averaging $2356.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$146K
  • Pfizer$141K
  • Global Blood Therapeutics, Inc.$137K
  • Astrazeneca UK Limited$32K
  • Daiichi Sankyo Inc.$32K

What the payments were for

  • Travel & lodging$85457%
  • Food & beverage$63443%

General payments by program year

19
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,489 in reported general payments places this provider in the 65th percentile of 132 pediatric hematology-oncology providers in Florida.

See all pediatric hematology-oncology providers in Florida

Other pediatric hematology-oncology in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →